Moderna Collaboration and License Agreement (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of March 31, 2024 (in thousands):

	Transaction price unsatisfied
Performance obligations:
Research and development	$	45,786
Option rights	45,000
Total performance obligations	$	90,786

Schedule of Changes in Deferred Revenue

The following table summarizes the changes in deferred revenue (in thousands):

	Three Months Ended March 31,
	2024		2023
Balance at the beginning of the period	$	46,413	$	47,459
Deferral of revenue	3,173		2,920
Recognition of unearned revenue	(3,397)		(3,243)
Balance at the end of the period	$	46,189	$	47,136